USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PROMILIAD BIOPHARMA, INC.
City: ALBERTON
State: MT
Zip+4: 59820-0010
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $684,959.00 3
STTR Phase I $707,264.00 4
STTR Phase II $2,516,144.00 2

Award List:

Natural feedstocks for diversity oriented synthesis

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: DARTMOUTH COLLEGE
Principal Investigator: Dennis L. Wright
Award Amount: $100,024.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific synthetic expertise and methodologies from the Wright Group at Dartmouth College to investigators at Promiliad Biopharma in an effort to reduce Promiliad's REBACS strategy to the level of… More

Potent and selective DHFR inhibitors for treating Cryptosporidiosis

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: Tufts University
Principal Investigator: Dennis L. Wright
Award Amount: $279,271.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific biophysical and synthetic expertise from the Anderson and Wright Groups at the University of Connecticut to investigators at Promiliad Biopharma in a joint effort to develop best-in- class… More

Isoindolinones as Antimicrobial Agents

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $225,624.00
Abstract:
DESCRIPTION (provided by applicant): Antibiotic resistance among common pathogens is a serious public health problem because it compromises our ability to treat many infectious diseases. The problem has been compounded by the lack of discovery of new antib iotics that act in novel ways. Such… More

New antibiotics targeting fatty acid biosynthesis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nigel Priestley
Award Amount: $171,569.00
Abstract:
DESCRIPTION (provided by applicant): Antibiotic resistant pathogens, such as methicillin-resistant Staphylococcus aureus, are a significant public health problem which is compounded by the slow rate of development of new antibiotics. Investigators at Merck Research Laboratories recently reported on… More

The identification of novel negative allosteric modulators of the nicotinic recep

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: OHIO STATE UNIVERSITY
Principal Investigator: Dennis B. Mckay
Award Amount: $190,807.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma w ith the expertise of Professor Dennis McKay… More

Potent Antifolates as New Therapeutics for MRSA

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency: HHS
Research Institution: University Of Connecticut Storrs
Principal Investigator: Dennis L. Wright – 860-486-9451
Award Amount: $1,517,864.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains… More

Selective MRTF/SRF-Transcription Inhibitors: Novel Anti-fibrotics for IPF

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nigel D. Priestley – 406-243-6251
Award Amount: $287,766.00
Abstract:
DESCRIPTION: Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of… More